Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 18/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10151293 | 0.92 | GPR119 (0.77) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL12596392 | 0.89 | GPR119 (0.56) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL12596657 | 0.87 | GPR119 (0.60) | GPR119CYP3A4CYP2C9CCNA2CDK2 | |
| SCHEMBL10169330 | 0.85 | GPR119 (0.73) | GPR119CYP3A4CYP2C9CCNA2CDK2 | |
| SCHEMBL10137695 | 0.85 | GPR119 (0.57) | GPR119CYP3A4CYP2C9CCNA2CDK2 | |
| SCHEMBL12596387 | 0.84 | GPR119 (0.44) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL10137743 | 0.81 | GPR119 (0.66) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL304338 | 0.81 | GPR119 (0.60) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL12596372 | 0.80 | CYP3A4 (0.78) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL12241540 | 0.80 | GPR119 (0.68) | GPR119CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118286-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS GPCR MODULATORS | SCHERING CORPORATION | 2011-05-19 | — | — | US | disclosed |
| US-20110118286-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS GPCR MODULATORS | SCHERING CORPORATION | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118286-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS GPCR MODULATORS | GPR119, GCGR, GPR35 | GPR119 1/4885CYP3A4 1059/4885CYP2C9 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.